3-(3,4-difluoro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine | 178372-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(3,4-difluoro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine
• 英文别名: 2-[3-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethanol；3-(3,4-difluorophenyl)-3-(2-hydroxyethyl)pyrrolidine；3-(3.4-difluorophenyl)-3-(2-hydroxyethyl)pyrrolidine；2-[3-(3,4-difluorophenyl)pyrrolidin-3-yl]ethanol
• CAS: 178372-33-3；191604-46-3；370865-49-9
• 化学式: C₁₂H₁₅F₂NO
• 分子量: 227.254
• InChiKey: IZSSEBICGAGEOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  330.3±42.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3,4-difluoro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine 生成 1-(3,4,5-trimethoxy-benzoyl)-3-(3,4-difluoro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine
  参考文献：
  名称：

  Substituted pyrrolidin-3-yl-alkyl-piperidines

  摘要：

  本发明涉及取代吡咯烷基哌啶基的化合物及其立体异构体和药学上可接受的盐以及其制备方法。本发明的化合物在药理活性方面具有用途，如快速激肽拮抗作用，特别是物质P和神经激肽A的拮抗作用等。具有快速激肽拮抗性质的化合物适用于与神经源性炎症和本文所述的其他疾病相关的情况。

  公开号：

  US05824690A1
• 作为产物：
  描述：

  3,4-二氟苯乙腈 在 镍 aluminium hydride 、 ammonium hydroxide 、 氢气 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 3-(3,4-difluoro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine
  参考文献：
  名称：

  Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists

  摘要：

  We recently described the synthesis and characterization of MDL 105,212, a non peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors.(1) Here we report the synthesis and structure-activity relationships for a series of analogs of MDL 105,212 with regards to: NK1 and NK2 receptor binding affinity, physical-chemical characterization; in vitro absorption potential; in vitro metabolic stability; and efficacy in a capsaicin-challenge conscious guinea pig model after oral administration. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10013-0

文献信息

• Carboxysubstituted cyclic carboxamide derivatives
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US05977139A1

  公开（公告）日：1999-11-02

  The present invention relates to novel carboxy substituted cyclic carboxamide derivatives of formula (1), ##STR1## and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, coughs and bronchitis.

  本发明涉及新型的带有羧基取代的环戊酰胺衍生物，化学式为(1)，##STR1##及其立体异构体和药学上可接受的盐，以及它们作为速激肽受体拮抗剂的用途。这类拮抗剂在治疗包括哮喘、咳嗽和支气管炎在内的速激肽介导的疾病和症状中很有用。
• Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06211199B1

  公开（公告）日：2001-04-03

  The present invention relates to novel substituted piperidine derivatives of formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

  本发明涉及一种新型的取代哌啶衍生物，其化学式为（1），其立体异构体以及药学上可接受的盐，这些衍生物可用作组胺受体拮抗剂和速激肽受体拮抗剂。这些拮抗剂在过敏性鼻炎的治疗中很有用，包括季节性鼻炎和鼻窦炎；炎症性肠病，包括克罗恩病和溃疡性结肠炎；哮喘；支气管炎；以及呕吐。
• Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases
  申请人：——

  公开号：US20010034343A1

  公开（公告）日：2001-10-25

  The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula 1 and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

  本发明涉及一种新颖的4-(1H-苯并咪唑-2-基)[1,4]二氮杂环庚烷衍生物及其立体异构体，以及其药学上可接受的盐，其作为组胺受体拮抗剂和速激肽受体拮抗剂具有用途。这些拮抗剂在过敏性鼻炎的治疗中有用，包括季节性鼻炎和鼻窦炎；炎症性肠病，包括克罗恩病和溃疡性结肠炎；哮喘；支气管炎；以及呕吐。
• Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06194406B1

  公开（公告）日：2001-02-27

  The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

  本发明涉及新颖的4-(1H-苯并咪唑-2-基)[1,4]二氮杂环庚烷衍生物的化合物（1）及其立体异构体，以及其药学上可接受的盐，这些化合物可用作组胺受体拮抗剂和速激肽受体拮抗剂。这些拮抗剂在过敏性鼻炎的治疗中很有用，包括季节性鼻炎和鼻窦炎；炎症性肠病，包括克罗恩病和溃疡性结肠炎；哮喘；支气管炎；以及呕吐。
• Heterocyclic tachykinin receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0714891A1

  公开（公告）日：1996-06-05

  This invention provides a novel series substituted piperidines, pyrrolidines, and hexamethyleneimines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds. The compounds have the formula wherein:    p is 1, 2, or 3;    m and n are independently 0-6;    X is         N-Ra, or CH-NRbRc,    where Ra, Rb, and Rc are independently selected from the group consisting of hydrogen and C1-C6 alkyl;    R1 and R2 are independently hydrogen, halo, trifluoromethyl, trichloromethyl, C1-C6 alkyl, or C1-C6 alkoxy; and    R3, R4, and R5 are independently selected from the group consisting of hydrogen, halo, trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, cyano, hydroxy, amino, -NHCONH2, nitro, -CONH2, C2-C10 alkenyl, C2-C10 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkoxy, C1-C10 alkylthio, C1-C10 alkylamino, C2-C6 alkanoyl, and C2-C6 alkanoyloxy; or a pharmaceutically acceptable salt or solvate thereof.

  本发明提供了一系列新型的取代哌啶、吡咯烷和六亚甲基亚胺，它们可用于治疗或预防与速激肽过量有关的生理紊乱。本发明还提供了治疗此类生理紊乱的方法以及采用这些新型化合物的药物制剂。这些化合物的化学式为 其中 p 是 1、2 或 3； m 和 n 独立地为 0-6 X 是 N-Ra，或 CH-NRbRc、 其中 Ra、Rb 和 Rc 独立地选自氢和 C1-C6 烷基组成的组； R1 和 R2 独立地为氢、卤代、三氟甲基、三氯甲基、C1-C6 烷基或 C1-C6 烷氧基；以及 R3、R4 和 R5 独立选自由氢、卤素、三氟甲基、C1-C6 烷基、C1-C6 烷氧基、氰基、羟基、氨基、-NHCONH2、硝基、-CONH2、C2-C10 烯基、C2-C10 炔基、C3-C8 环烷基、C3-C8 环烯基、C3-C8 环烷氧基、C1-C10 烷硫基、C1-C10 烷基氨基、C2-C6 烷酰基和 C2-C6 烷酰氧基组成的组； 或其药学上可接受的盐或溶液。